Previous 10 | Next 10 |
2024-01-26 17:30:00 ET Summary MoneyShow presents top investment ideas for 2024 from their contributors. This year’s edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations tha...
2024-01-17 16:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-29 08:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 th at 5:05 pm ET. A webcast of the presentation will be av...
2023-11-17 13:08:02 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The article embarks on a transformative journey through the biotech frontier, where the listed companies stand as titans reshaping healthcare norms. The first one’s strategic collabo...
2023-11-10 12:14:28 ET More on Celldex Celldex: Mast Cell Disease Targeting Continues To Make Advancements In Clinic Celldex Therapeutics announces pricing of public offering of common stock Celldex Therapeutics announces proposed public offering of common stock ...
2023-11-08 15:22:43 ET Summary Positive results achieved from phase 1b study using barzolvolimab for the treatment of patients with prurigo nodularis; Phase 2 multi-dose study to be initiated in early 2024. Positive results from a phase 2 study using barzolvolimab for the treatmen...
2023-11-08 04:17:34 ET More on Celldex Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU Celldex Therapeutics announces proposed public offering of common stock Biggest stock movers today: Paramount Global, Organigram, Celldex Therapeutics and...
HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 7,425,000 shares of its common stock at a public offering price of $27.00...
2023-11-07 16:06:59 ET More on Celldex Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU Biggest stock movers today: Paramount Global, Organigram, Celldex Therapeutics and more Celldex jumps premarket on positive topline results from urticaria...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...